In 2024, the global leukapheresis market generated USD 79.9 million in revenue, and it is anticipated to grow at a 9.3% Compound Annual Growth Rate (CAGR) from 2024 to 2030, ultimately reaching USD 136.3 million by 2030.
This market expansion is driven by several factors, including the increasing prevalence of leukemia and other blood-related disorders, rising government initiatives promoting cancer awareness, a growing global volume of blood donations, rapid advancements in technology, and heightened research on leukoplakias for use in clinical studies.
Leukapheresis is a medical procedure used to treat chronic lymphocytic leukemia and other blood cancers. The rising number of leukemia patients, largely due to sedentary lifestyles, smoking, and exposure to radiation and harmful chemicals, is contributing to the market’s growth. Additional risk factors include infections from HIV, Epstein–Barr virus, and human T-cell leukemia/lymphoma virus.
Governments worldwide are implementing various initiatives to combat leukemia, starting with increasing awareness about the disease. In addition, several governments have introduced reimbursement policies and established specialized cancer hospitals and oncology centers.
Another significant factor driving the leukapheresis market is the growing number of blood donors globally. Blood components such as platelets and red blood cells (RBCs) can be replaced through transfusions using donor blood.
Leukemia patients often undergo chemotherapy, which can temporarily damage their immune systems and blood cells. As a result, leukapheresis serves as a crucial supplementary treatment, as donated blood provides healthy white blood cells (WBCs) and RBCs to cancer patients. The growing number of blood donations worldwide is simplifying this process.
The market is segmented into disposables and devices based on product type, with disposables dominating the market in recent years. This trend is expected to continue, as the increasing prevalence of leukemia drives the demand for leukapheresis disposables. Proper use of disposables also helps reduce the risk of infections during blood transfusions.
North America held the largest market share in recent years, accounting for approximately 50% of the global leukapheresis market. The region is expected to maintain its dominance, driven by significant research and development (R&D) activities in the biotechnology and pharmaceutical sectors. Additionally, the presence of numerous market players, healthcare professionals, and ongoing CAR T-cell therapy clinical trials further strengthens North America’s position. The region’s susceptibility to infectious and pandemic diseases also contributes to its market growth.